OBS Chapter 350: The company broke 3000 billion yuan immediately after its listing.
Chapter 350: The company broke 3000 billion yuan immediately after its listing.
……
"no problem,"
Chen Xuan nodded and agreed immediately.
He is quite satisfied with the sales volume.
Although the sales volume is similar to that of the Chinese market, the profits are different.
In the first year, there were 1000 million boxes, and based on the factory price of 5000 yuan per box, that was 500 billion yuan. In the following year, there were 1500 million boxes, and the revenue reached 750 billion yuan.
If calculated over four years, that would be 2750 billion in revenue.
As for profits, there is no need to mention that the profit margin in overseas markets is much higher than that in the Chinese market.
This is just a relatively conservative sales estimate. The actual sales volume should be higher than this number, so the revenue and profit will only be higher than this estimate.
The gap between the two markets is indeed very large, especially when the price difference is particularly large, the gap will only be more exaggerated.
Chinese market plus overseas market.
The effective drug for lung cancer has just been launched on the market and has already generated more than 3000 billion in revenue.
This can indeed be regarded as a sales myth in the pharmaceutical industry. Except for some special cases, it is almost impossible for other drugs to achieve this kind of revenue when they are first launched on the market.
If this revenue were to be exposed, it would probably shock the whole world.
Even though everyone knows that the market for lung cancer-specific drugs is huge, the high level of attention it has received before shows how great the demand for this drug is.
But it still seems incredible to everyone that the lung cancer drug can generate more than 3000 billion in revenue just after it was launched on the market.
Judging from the current situation, the lung cancer specific drug has the potential to become the world's top medicine.
Of course, the premise is that Antai Pharmaceutical Group’s subsequent new drugs do not show greater potential, otherwise it is difficult to say.
But what is certain is that the title of Global Medicine King will definitely belong to Antai Pharmaceutical Group.
"Have you decided on the retail price?" Chen Xuan had no objection to Novartis' order volume.
This order is very reasonable and relatively conservative, but not small either. 1000 million boxes in the first year is already very good.
For many best-selling drugs, in their first year, they don’t even sell 1/10 of 1000 million boxes, which is already considered a very strong order.
Therefore, he is more concerned about the retail price of the lung cancer drug, which is a point on which the two parties have not yet reached a formal agreement.
If the retail price is beyond his acceptable range, he may have to look for new partners.
After all, if the retail price is ridiculously high, there will definitely not be much sales overseas. Even if it is handed over to Novartis for agency, it will only waste such a large market.
The factory price of the lung cancer drug is already very high. If Novartis continues to raise the price, the final sales volume will definitely be very low. Only a very small number of wealthy people can afford this drug.
Therefore, Chen Xuan needs to understand this now so that he can decide whether to cooperate with Novartis.
He can allow Novartis to make money. Of course, the purpose of doing business is to make money. You can't just make money for yourself and ask others to work for you for free.
Of course, he would never have such an idea, but he couldn't make too much money. If he raised the price too high, it would affect the sales of the lung cancer drug and his income.
If it were other drugs, he might not have much say.
But the situation is different for the lung cancer drug, which is destined to be a global bestseller. He naturally has the right to choose his partners and decide the final retail price.
If he is not satisfied with Novartis's retail price, he can also change to other agents immediately.
"According to Mr. Chen's meaning,"
"We have decided that the retail price of the lung cancer drug, excluding tax, will be around 5500 yuan per box, and the highest price will not exceed 6000 yuan."
Anna naturally understood what Chen Xuan meant, and she responded immediately.
Naturally, the retail prices in different countries cannot be exactly the same. Some are high and some are low, and they will also be adjusted according to different exchange rates.
5500 yuan per box is converted into Chinese currency.
Chen Xuan could accept this price.
Basically, this is not too much, Novartis only makes about 10% profit.
If other expenses are taken into account, there may not even be a 10% profit, and the only thing we can do is to sell at a low price but high volume.
Of course, the reason why the price is tax-exclusive is because the medical tax rates in different countries are different. In addition, this is a medicine exported by China, so additional tariffs may be imposed.
In this case, the final retail price plus these taxes and fees will definitely be more than 5500 yuan.
But this is money collected by various governments, and it is not something Novartis can decide.
Novartis naturally cannot promise a retail price of 5500 yuan including tax. After all, the tariffs of many countries plus the local tax rates are likely to be more than 5500 yuan. It is impossible to let Novartis be the agent of the drug and have to pay this money.
Therefore, the current tax-free policy is a very reasonable business practice and is not excessive at all.
"No problem, you can sell it for a while."
“Once the market is saturated at this price point, we can start lowering prices to cover a larger patient population.”
Chen Xuan agreed to the retail price and also raised a new point.
The situation in the Chinese market is not bad. The monthly medicine cost is only 5000 yuan. After medical insurance reimbursement, it can basically be reduced to 2000 yuan per month.
This price is enough to cover most patient groups. There is no need to lower the price later. It is enough to maintain the supply of the drug.
But it's different overseas.
The monthly medicine cost will basically not be less than 25000.
In other words, it is equivalent to more than ten times the amount after Huaxia reimbursement.
Even in developed countries with higher incomes, it is not so easy to afford such medical expenses.
Unless there is commercial insurance to cover the cost, it will not be easy to afford such medical expenses.
What's more, not all countries are developed countries, and not all patients are high-income groups. There are also many patients with middle and low incomes.
Faced with such drug prices, it is unaffordable after all, and you will eventually not be able to afford the drugs.
This part of the patient group should be considered the largest group and the largest market.
So Chen Xuan naturally would not miss such a big market.
But now we have to make money from the rich first.
"Understood. We will cooperate when the time comes."
Anna nodded in agreement immediately.
She naturally knew that the price of the medicine could not be fixed for a long time.
As long as the market begins to become saturated, it is necessary to open up a larger market in order to gain more profits.
"Antai Pharmaceutical Group's production business is becoming increasingly heavy."
"I think Mr. Chen should consider expanding the production capacity of Antai Pharmaceutical Group."
"Otherwise, Antai Pharmaceutical Group's subsequent production will face increasing pressure and may not be able to keep up with demand."
After the matter was settled, Anna brought up this point again.
She didn't ask this question for no reason.
On the one hand, she was worried that Antai Pharmaceutical Group's production capacity was insufficient, which would affect its supply to Novartis.
Judging from the market potential of lung cancer-specific drugs, the demand will be very large both now and in the future, and this will become the first choice for patients.
Chen Xuan also publicly promised to give priority to supplying the Chinese market.
In this way, if production capacity becomes tight in the future, it is likely that it will not be able to keep up with demand, and the supply to Novartis will be relatively small.
Anna was naturally worried about this situation, so she hoped that Antai Pharmaceutical Group could increase its production capacity.
Moreover, she hopes that Novartis can also gain some share as Antai Pharmaceutical Group expands.
……